March 3, 2026
HRSA Requests Feedback on 340B Rebate Model Pilot, Comment by April 20
The Health Resources and Services Administration (HRSA) issue a Request for Information (RFI) to solicit stakeholder input regarding the potential use of rebates to effectuate the ceiling price under the 340B Program, including the standards and procedures that should govern the approval of manufacturer rebate plans and the impacts on all stakeholders.
This RFI seeks comments on whether HRSA should implement a rebate model under the 340B Program and how best to operationalize any such rebate framework for stakeholders. The information collected through this RFI will assist HRSA in evaluating the operational, financial, and drug access for patients of a rebate model on covered entities, manufacturers, and other stakeholders across the drug supply chain.
To provide stakeholders additional time to submit meaningful comments for HRSA’s review in evaluating operational, financial, and potential impacts on access to drugs for patients under a rebate model, HRSA has extended the comment period from 30 days to 60 days. Feedback on the RFI is due no later than April 20, 2026.
In addition, in compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act, HRSA seeks comments from the public regarding the burden estimate or any other aspect of the Information Collection Request (ICR), related to a potential 340B Rebate Model Pilot Program.
Comments on this ICR should be received no later than April 27, 2026.
Click Here to Learn More and Comment on 340B Rebate Model Pilot Program,- April 20 deadline
Click Here to Learn More and Comment on Agency Information Collection Activities, April 27 deadline